Incyte Corporation (NASDAQ:INCY) shares fell -1.88% in last trading session and ended the day at $68.45. INCY Gross Margin is 96.40% and its has a return on assets of 0.70%. Incyte Corporation (NASDAQ:INCY) quarterly performance is -38.07%.
Incyte Corporation (Nasdaq: INCY) announces that ten abstracts featuring data from its emerging development portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana from April 16–20, 2016. These abstracts include data from the Company’s monoclonal antibody agonist programs targeting GITR and OX40 as well as its small molecule inhibitor programs targeting LSD1, BRD (BET), PI3Kδ and JAK1.
SeaWorld Entertainment, Inc. (NYSE:SEAS) ended the last trading day at $20.43. Company weekly volatility is calculated as 2.70% and price to cash ratio as 94.64. SeaWorld Entertainment, Inc. (NYSE:SEAS) showed a weekly performance of 2.30%.
On 17 March, SeaWorld Entertainment, Inc. (NYSE: SEAS), a leading theme park and entertainment company, announced that the killer whales – or orcas – currently in the company’s care will be the last generation of orcas at SeaWorld.
On 28 March, Astec Industries, Inc. (NASDAQ:ASTE) shares fell -0.04% and was closed at $44.68. ASTE EPS growth in last 5 year was -0.80%. Astec Industries, Inc. (NASDAQ:ASTE) year to date (YTD) performance is 10.02%.
Astec Industries, Inc. (NASDAQ:ASTE) announces that it attend the BB&T Capital Markets 10th Annual Commercial & Industrial Investor Conference in Coral Gables, Florida on Thursday, March 24, 2016. Richard J. Dorris, Executive Vice President and Chief Operating Officer and Stephen C. Anderson, Vice President of Administration and Director of Investor Relations attend the conference.
Argos Therapeutics, Inc. (NASDAQ:ARGS) shares advanced 12.52% in last trading session and ended the day at $6.11. ARGS has a return on assets of -139.10%. Argos Therapeutics, Inc. (NASDAQ:ARGS) quarterly performance is 146.37%.
On 23 March, Argos Therapeutics, Inc. (NASDAQ:ARGS) announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC).
SM Energy Company (NYSE:SM) caters to the Basic Materials space. It has a net profit margin of -29.60% and weekly performance is -2.40%. On the last day of trading company shares ended up at $17.91. SM Energy Company (NYSE:SM) distance from 50-day simple moving average (SMA50) is 37.63%.
On March 24, 2016, William Gardiner notified the Board of Directors of SM Energy Company (NYSE:SM) of his intention not to stand for re-election to the Board at the Company’s 2016 Annual Meeting of Stockholders. Mr. Gardiner’s term of office as a director will expire at the conclusion of the 2016 Annual Meeting. In connection with Mr. Gardiner’s announcement and pursuant to the Company’s Amended and Restated By-laws, the Board of Directors adopted a resolution to reduce the size of the Board to eight directors immediately upon Mr. Gardiner’s retirement. Mr. Gardiner has served as a director of the Company since 1999. Mr. Gardiner’s decision not to stand for re-election is not as a result of any disagreement with the Company or the Board of Directors.